Please login to the form below

Not currently logged in
Email:
Password:

S-A's Lovenox loses out to J&J/ Bayer's rivaroxaban

Bayer and J&J's experimental blood thinner rivaroxaban leads to fewer clots and deaths in patients after hip surgery than sanofi-aventis' Lovenox

Germany-headquartered Bayer and US-based Johnson & Johnson's (J&J) experimental blood thinner rivaroxaban leads to fewer clots and deaths in patients after hip surgery than sanofi-aventis' (S-A) Lovenox (enoxaparin).

About 1.1 per cent of patients had serious blood clots or died on the Bayer and J&J pill, compared with 3.7 per cent of those taking S-A's injected medicine, Lovenox, according to research reported today at a meeting of the American Society of Hematology. Both drugs had similar rates of bleeding, a side effect of anti-clotting medications.

Rivaroxaban may enable J&J and Bayer to wrest market share from the injectable Lovenox, which was S-A's best-selling treatment in FY06, racking up USD 3.5bn. Bayer has asked EU regulators to allow sale of the drug under the brand name Xarelto in October 2007.

Bengt Eriksson, an orthopaedic surgeon at Sahlgrenska University Hospital in Gothenburg, Sweden, and the study's lead author, said: "The results were quite astonishing. It was a big surprise for the new drug to demonstrate superior effectiveness, instead of merely showing about equal effectiveness."

Patients were given either Lovenox or rivaroxaban for five weeks after hip-replacements. Studies of the J&J and Bayer drug in other major orthopaedic surgery will be presented at the ASH meeting on 10 December. 

Lloyd Haskell, a vice president at J&JPRD, was quoted as saying: "This drug was measured against Lovenox, which is the gold standard, and we got more efficacy without paying a price in terms of any extra bleeding."

If approved, rivaroxaban will be marketed by J&J in the US and by Bayer in the rest of the world. Bayer has projected peak sales of USD 2.9bn, while J&J has said it will seek US marketing approval in H2 2008.

9th December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics